Eva Hoferkova (Eva Vojackova)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 11

Top Topics

Chronic Lymphocytic Leukemia

Signaling Pathway

Cell Proliferation

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)
Eva Hoferkova, Vaclav Seda, Sona Kadakova, Jan Verner, Tomas Loja, Kvetoslava Matulova, Hana Skuhrova Francova, Eva Ondroušková, Daniel Filip, Nicolas Blavet, Miroslav Boudny, Gabriela Mladonicka Pavlasova, Josef Vecera, Laura Ondrisova, Petra Pavelkova, Krystof Hlavac, Lenka Kostalova, Androniki Michaelou, Sarka Pospisilova, Jana Dorazilova, Václav Chochola, Josef Jaros, Michael Doubek, Marie Jarosova, Ales Hampl, Lucy Vojtova, Leos Kren, Jiří Mayer, Marek Mraz
Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs. Leukemia 38 (8) (2024)
Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)
Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)
Eva Hoferkova, Vaclav Seda, Sona Kadakova, Jan Verner, Tomas Loja, Kvetoslava Matulova, Hana Skuhrova Francova, Eva Ondroušková, Daniel Filip, Nicolas Blavet, Miroslav Boudny, Gabriela Mladonicka Pavlasova, Josef Vecera, Laura Ondrisova, Petra Pavelkova, Krystof Hlavac, Lenka Kostalova, Androniki Michaelou, Sarka Pospisilova, Jana Dorazilova, Václav Chochola, Josef Jaros, Michael Doubek, Marie Jarosova, Ales Hampl, Lucy Vojtova, Leos Kren, Jiří Mayer, Marek Mraz
Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs. Leukemia (2024)
Eva Hoferkova, Vaclav Seda, Sona Kadakova, Jan Verner, Tomas Loja, Kvetoslava Matulova, Hana Skuhrova Francova, Eva Ondroušková, Daniel Filip, Nicolas Blavet, Miroslav Boudny, Gabriela Mladonicka Pavlasova, Josef Vecera, Laura Ondrisova, Petra Pavelkova, Krystof Hlavac, Lenka Kostalova, Androniki Michaelou, Sarka Pospisilova, Jana Dorazilova, Václav Chochola, Josef Jaros, Michael Doubek, Marie Jarosova, Ales Hampl, Lucy Vojtova, Leos Kren, Jiří Mayer, Marek Mraz
Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs. Leukemia 38 (8) (2024)
Eva Hoferkova, Vaclav Seda, Sona Kadakova, Jan Verner, Tomas Loja, Kvetoslava Matulova, Hana Skuhrova Francova, Eva Ondroušková, Daniel Filip, Nicolas Blavet, Miroslav Boudny, Gabriela Mladonicka Pavlasova, Josef Vecera, Laura Ondrisova, Petra Pavelkova, Krystof Hlavac, Lenka Kostalova, Androniki Michaelou, Sarka Pospisilova, Jana Dorazilova, Václav Chochola, Josef Jaros, Michael Doubek, Marie Jarosova, Ales Hampl, Lucy Vojtova, Leos Kren, Jiří Mayer, Marek Mraz
Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs. Leukemia 38 (8) (2024)
Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Anděra, Marek Trněný, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status. Blood advances (2024)
Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)
Eva Hoferkova, Sona Kadakova, Marek Mraz
In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing. Cancers 14 (13) (2022)
Vaclav Seda, Eva Hoferkova, Laura Ondrisova, Lenka Kostalova, Sonali Sharma, Tomas Loja, Gabriela Mladonicka Pavlasova, Daniel Zicha, Marie Kudlickova Peskova, Jan Krivanek, Kvetoslava Liskova, Leos Kren, Vladimir Benes, Katerina Musilova Litzmanova, Marek Borsky, Jan Oppelt, Jan Verner, Sarka Pospisilova, Yvona Brychtova, Anna Panovska, Zhi Tan, Shuxing Zhang, Michael Doubek, Katerina Amruz Cerna, Jiri Mayer, Marek Mraz
FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia. Blood 138 (9) (2021)